In most patients with a definite clinical diagnosis of HF, there is no confirmatory role for routine genetic testing to establish the diagnosis. Genetic counselling is recommended in patients with HCM, idiopathic DCM and ARVC. Restrictive cardiomyopathy and isolated non-compaction cardiomyopathies are of a possible genetic origin and should also be considered for genetic testing. HCM is mostly inherited as an autosomal dominant disease with variable expressivity and age-related penetrance. Currently, more than 20 genes and 1400 mutations have been identified, most of which are located in the sarcomere genes encoding cardiac b-myosin heavy chain (MYH7) and cardiac myosin binding protein C (MYBPC3). 88, 122 DCM is idiopathic in 50% of cases, about one-third of which are hereditary. There are already more than 50 genes identified that are associated with DCM. Many genes are related to the cytoskeleton. The most frequent ones are titin (TTN), lamin (LMNA) and desmin (DES). 88, 123 ARVC is hereditary in most cases and is caused by gene mutations that encode elements of the desmosome. Desmosomal gene mutations explain 50% of cases and 10 genes are currently associated with the disease.
124
Counselling should be performed by someone with sufficient knowledge of the specific psychological, social and medical implications of a diagnosis. Determination of the genotype is important, since some forms [e.g. mutations in LMNA and phospholamban (PLN) ] are related to a poorer prognosis. DNA analysis could also be of help to establish the diagnosis of rare forms, such as mitochondrial cardiomyopathies. Screening of first-degree relatives for early detection is recommended from early adolescence onwards, although earlier screening may be considered depending on the age of disease onset in other family members.
Recently, the MOGE(S) classification of inherited cardiomyopathies has been proposed, which includes the morphofunctional phenotype (M), organ(s) involvement (O), genetic inheritance pattern (G), aetiological annotation (E), including genetic defect or underlying disease/ substrate, and the functional status (S) of the disease. 125 6. Delaying or preventing the development of overt heart failure or preventing death before the onset of symptoms There is considerable evidence that the onset of HF may be delayed or prevented through interventions aimed at modifying risk factors for HF or treating asymptomatic LV systolic dysfunction (see recommendations table). Many trials show that control of hypertension will delay the onset of HF and some also show that it will prolong life. 126 -129 Different antihypertensive drugs [diuretics, ACEIs, angiotensin receptor blockers (ARBs), beta-blockers] have been shown to be effective, especially in older people, both in patients with and without a history of myocardial infarction. 126 -128 Along with the ongoing discussion on optimal target blood pressure values in hypertensive non-diabetic subjects, the recent SPRINT study has already demonstrated that treating hypertension to a lower goal [systolic blood pressure (SBP) ,120 mmHg vs. ,140 mmHg] in older hypertensive subjects (≥75 years of age) or high-risk hypertensive patients reduces the risk of cardiovascular disease, death and hospitalization for HF. 129 Recently, empaglifozin (an inhibitor of sodium-glucose cotransporter 2), has been shown to improve outcomes (including the reduction of mortality and HF hospitalizations) in patients with type 2 diabetes. 130 Other hypoglycaemic agents have not been shown convincingly to reduce the risk of cardiovascular events and may increase the risk of HF. Intensification of hypoglycaemic therapy to drive down glycated haemoglobin (HbA1c) with agents other than empagliflozin does not reduce the risk of developing HF (for details see Section 11.6 on diabetes). Although smoking cessation has not been shown to reduce the risk of developing HF, the epidemiological associations with the development of cardiovascular disease 131 suggest that such advice, if followed, would be beneficial. The association between alcohol intake and the risk of developing de novo HF is U-shaped, with the lowest risk with modest alcohol consumption (up to 7 drinks/week). 132 -134 Greater alcohol intake may trigger the development of toxic cardiomyopathy, and when present, complete abstention from alcohol is recommended. An inverse relationship between physical activity and the risk of HF has been reported. A recent meta-analysis found that doses of physical activity in excess of the guideline recommended minimal levels may be required for more substantial reductions in HF risk. 135 It has been shown that among subjects ≥40 years of age with either cardiovascular risk factors or cardiovascular disease (but neither asymptomatic LV dysfunction nor overt HF), BNP-driven collaborative care between the primary care physician and the specialist cardiovascular centre may reduce the combined rates of LV systolic dysfunction and overt HF. 136 Statins reduce the rate of cardiovascular events and mortality; there is also reasonable evidence that they prevent or delay the onset of HF. 137 -140 Neither aspirin nor other antiplatelet agents, nor revascularization, have been shown to reduce the risk of developing HF or mortality in patients with stable CAD. Obesity is also a risk factor for HF, 141 but the impact of treatments of obesity on the development of HF is unknown. In patients with CAD, without LV systolic dysfunction or HF, ACEIs prevent or delay the onset of HF and reduce cardiovascular and allcause mortality, although the benefit may be small in the contemporary setting, especially in patients receiving aspirin.
142
Up-titration of renin-angiotensin system antagonists and beta-blockers to maximum tolerated dosages may improve outcomes, including HF, in patients with increased plasma concentrations of NPs. 136, 143 A primary percutaneous coronary intervention (PCI) at the earliest phase of an ST segment elevation myocardial infarction (STEMI) to reduce infarct size decreases the risk of developing a substantial reduction in LVEF and subsequent development of HFrEF.
112 Initiation of an ACEI, a beta-blocker and an MRA immediately after a myocardial infarction, especially when it is associated with LV systolic dysfunction, reduces the rate of hospitalization for HF and mortality, 144 -148 as do statins.
-139
In asymptomatic patients with chronically reduced LVEF, regardless of its aetiology, an ACEI can reduce the risk of HF requiring hospitalization. 5, 144, 145 This has not yet been shown for beta-blockers or MRAs.
In patients with asymptomatic LV systolic dysfunction (LVEF ,30%) of ischaemic origin who are ≥40 days after an AMI, an implantable cardioverter-defibrillator (ICD) is recommended to prolong life. 149 7. Pharmacological treatment of heart failure with reduced ejection fraction 7.1 Objectives in the management of heart failure The goals of treatment in patients with HF are to improve their clinical status, functional capacity and quality of life, prevent hospital admission and reduce mortality. The fact that several drugs for HF have shown detrimental effects on long-term outcomes, despite showing beneficial effects on shorter-term surrogate markers, has led regulatory bodies and clinical practice guidelines to seek mortality/morbidity data for approving/recommending therapeutic interventions for HF. However, it is now recognized that preventing HF hospitalization and improving functional capacity are important benefits to be considered if a mortality excess is ruled out.
-161
Figure 7.1 shows a treatment strategy for the use of drugs (and devices) in patients with HFrEF. The recommendations for each treatment are summarized below.
Neuro-hormonal antagonists (ACEIs, MRAs and beta-blockers) have been shown to improve survival in patients with HFrEF and are recommended for the treatment of every patient with HFrEF, unless contraindicated or not tolerated. A new compound (LCZ696) that combines the moieties of an ARB (valsartan) and a neprilysin (NEP) inhibitor (sacubitril) has recently been shown to be superior to an ACEI (enalapril) in reducing the risk of death and of hospitalization for HF in a single trial with strict inclusion/exclusion criteria.
162 Sacubitril/valsartan is therefore recommended to replace ACEIs in ambulatory HFrEF patients who remain symptomatic despite optimal therapy and who fit these trial criteria. ARBs have not been consistently proven to reduce mortality in patients with HFrEF and their use should be restricted to patients intolerant of an ACEI or those who take an ACEI but are unable to tolerate an
Recommendations to prevent or delay the development of overt heart failure or prevent death before the onset of symptoms MRA. Ivabradine reduces the elevated heart rate often seen in HFrEF and has also been shown to improve outcomes, and should be considered when appropriate.
The above medications should be used in conjunction with diuretics in patients with symptoms and/or signs of congestion. The use of diuretics should be modulated according to the patient's clinical status.
The key evidence supporting the recommendations in this section is given in Web Table 7 .1. The recommended doses of these disease-modifying medications are given in Table 7 .2. The recommendations given in Sections 7.5 and 7.6 summarize drugs that should be avoided or used with caution in patients with HFrEF.
7.2 Treatments recommended in all symptomatic patients with heart failure with reduced ejection fraction 7.2.1 Angiotensin-converting enzyme inhibitors ACEIs have been shown to reduce mortality and morbidity in patients with HFrEF 2,5,163 -165 and are recommended unless contraindicated or not tolerated in all symptomatic patients. ACEIs should be up-titrated to the maximum tolerated dose in order to achieve adequate inhibition of the renin -angiotensin -aldosterone system (RAAS). There is evidence that in clinical practice the majority of patients receive suboptimal doses of ACEI. 166 ACEIs are also recommended in patients with asymptomatic LV systolic dysfunction to reduce the risk of HF development, HF hospitalization and death (see Section 6).
Pharmacological treatments indicated in patients with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction Practical guidance on how to use ACE inhibitors is given in Web Table 7 .4.
Beta-blockers
Beta-blockers reduce mortality and morbidity in symptomatic patients with HFrEF, despite treatment with an ACEI and, in most cases, a diuretic, 167, 168, 170, 172, 173 but have not been tested in congested or decompensated patients. There is consensus that beta-blockers and ACEIs are complementary, and can be started together as soon as the diagnosis of HFrEF is made. There is no evidence favouring the initiation of treatment with a beta-blocker before an ACEI has been started. 176 Betablockers should be initiated in clinically stable patients at a low dose and gradually up-titrated to the maximum tolerated dose. In patients admitted due to acute HF (AHF) beta-blockers should be cautiously initiated in hospital, once the patient is stabilized. An individual patient data meta-analysis of all the major betablocker trials in HFrEF has shown no benefit on hospital admissions and mortality in the subgroup of patients with HFrEF who are in AF.
177 However, since this is a retrospective subgroup analysis, and because beta-blockers did not increase the risk, the guideline committee decided not to make a separate recommendation according to heart rhythm. Beta-blockers should be considered for rate control in patients with HFrEF and AF, especially in those with high heart rate (see Section 10.1 for details). Beta-blockers are recommended in patients with a history of myocardial infarction and asymptomatic LV systolic dysfunction to reduce the risk of death (see Section 6).
Practical guidance on how to use beta-blockers is given in Web Table 7 .5.
Mineralocorticoid/aldosterone receptor antagonists
MRAs (spironolactone and eplerenone) block receptors that bind aldosterone and, with different degrees of affinity, other steroid hormone (e.g. corticosteroids, androgens) receptors. Spironolactone or eplerenone are recommended in all symptomatic patients (despite treatment with an ACEI and a beta-blocker) with HFrEF and LVEF ≤35%, to reduce mortality and HF hospitalization. 174, 175 Caution should be exercised when MRAs are used in patients with impaired renal function and in those with serum potassium levels .5.0 mmol/L. Regular checks of serum potassium levels and renal function should be performed according to clinical status.
Practical guidance on how to use MRAs is given in Web Table 7 .6.
7.3 Other treatments recommended in selected symptomatic patients with heart failure with reduced ejection fraction 7.3.1 Diuretics Diuretics are recommended to reduce the signs and symptoms of congestion in patients with HFrEF, but their effects on Figure 7 .1 Therapeutic algorithm for a patient with symptomatic heart failure with reduced ejection fraction. Green indicates a class I recommendation; yellow indicates a class IIa recommendation. ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ARNI ¼ angiotensin receptor neprilysin inhibitor; BNP ¼ B-type natriuretic peptide; CRT ¼ cardiac resynchronization therapy; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; H-ISDN ¼ hydralazine and isosorbide dinitrate; HR ¼ heart rate; ICD HF within the last 6 months or with elevated natriuretic peptides (BNP . 250 pg/ml or NTproBNP . 500 pg/ml in men and 750 pg/ml in women). f With an elevated plasma natriuretic peptide level (BNP ≥ 150 pg/mL or plasma NT-proBNP ≥ 600 pg/mL, or if HF hospitalization within recent 12 months plasma BNP ≥ 100 pg/mL or plasma NT-proBNP ≥ 400 pg/mL). mortality and morbidity have not been studied in RCTs. A Cochrane meta-analysis has shown that in patients with chronic HF, loop and thiazide diuretics appear to reduce the risk of death and worsening HF compared with placebo, and compared with an active control, diuretics appear to improve exercise capacity. 178, 179 Loop diuretics produce a more intense and shorter diuresis than thiazides, although they act synergistically and the combination may be used to treat resistant oedema. However, adverse effects are more likely and these combinations should only be used with care. The aim of diuretic therapy is to achieve and maintain euvolaemia with the lowest achievable dose. The dose of the diuretic must be adjusted according to the individual needs over time. In selected asymptomatic euvolaemic/hypovolaemic patients, the use of a diuretic drug might be (temporarily) discontinued. Patients can be trained to self-adjust their diuretic dose based on monitoring of symptoms/signs of congestion and daily weight measurements.
Doses of diuretics commonly used to treat HF are provided in Table 7 .3. Practical guidance on how to use diuretics is given in Web Table 7 .7. 
If-channel inhibitor
Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm despite treatment with an evidence-based dose of betablocker (or maximum tolerated dose below that), ACE-I (or ARB), and an MRA (or ARB).
IIa B 180
Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with LVEF ≤35%, in sinus rhythm and a resting heart rate ≥70 bpm who are unable to tolerate or have contra-indications for a beta-blocker. Patients should also receive an ACE-I (or ARB) and an MRA (or ARB).
IIa C 181

ARB
An ARB is recommended to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients unable to tolerate an ACE-I (patients should also receive a beta-blocker and an MRA).
I B 182
An ARB may be considered to reduce the risk of HF hospitalization and death in patients who are symptomatic despite treatment with a beta-blocker who are unable to tolerate an MRA. IIb C -
Hydralazine and isosorbide dinitrate
≤35% or with an LVEF <45% combined with a dilated LV in NYHA Class III-IV despite treatment with an ACE-I a beta-blocker and an MRA to reduce the risk of HF hospitalization and death.
IIa B 183
Hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither an ACE-I nor an ARB (or they are contra-indicated) to reduce the risk of death.
IIb B 184
Digoxin
Digoxin may be considered in symptomatic patients in sinus rhythm despite treatment with an ACE-I (or ARB), a beta-blocker and an MRA, to reduce the risk of hospitalization (both all-cause and HF-hospitalizations). and mortality in patients with ambulatory, symptomatic HFrEF with LVEF ≤40% (this was changed to ≤35% during the study), elevated plasma NP levels (BNP ≥150 pg/mL or NT-proBNP ≥600 pg/mL or, if they had been hospitalized for HF within the previous 12 months, BNP ≥100 pg/mL or NT-proBNP ≥400 pg/mL), and an estimated GFR (eGFR) ≥30 mL/min/ Despite the superiority of sacubitril/valsartan over enalapril in the PARADIGM-HF trial, some relevant safety issues remain when initiating therapy with this drug in clinical practice. Symptomatic hypotension was more often present in the sacubitril/ valsartan group (in those ≥75 years of age, it affected 18% in the sacubitril/valsartan group vs. 12% in the enalapril group), although there was no increase in the rate of discontinuation.
IIb
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The risk of angioedema in the trial was reduced by recruiting only those who tolerated therapy with enalapril 10 mg b.i.d. and an sacubitril/valsartan during an active run-in phase of 5 -9 weeks (it resulted in a 0.4% rate of angioedema in sacubitril/valsartan group vs. 0.2% in an enalapril group). Also, the number of African American patients, who are at a higher risk of angioedema, was relatively small in this study. To minimize the risk of angioedema caused by overlapping ACE and neprilysin inhibition, the ACEI should be withheld for at least 36 h before initiating sacubitril/valsartan. Combined treatment with an ACEI (or ARB) and sacubitril/valsartan is contraindicated. There are additional concerns about its effects on the degradation of beta-amyloid peptide in the brain, which could theoretically accelerate amyloid deposition. 189 -191 However, a recent small 14-day study with healthy subjects showed elevation of the beta-amyloid protein in the soluble rather than the aggregable form, which if confirmed over longer time periods in patients with HFrEF may indicate the cerebral safety of sacubitril/valsartan. 192 Long-term safety needs to be addressed.
I f -channel inhibitor
Ivabradine slows the heart rate through inhibition of the I f channel in the sinus node and therefore should only be used for patients in sinus rhythm. Ivabradine reduced the combined endpoint of mortality and hospitalization for HF in patients with symptomatic HFrEF and LVEF ≤35%, in sinus rhythm and with a heart rate ≥70 beats per minute (bpm) who had been hospitalized for HF within the previous 12 months, receiving treatment with an evidence-based dose of beta-blocker (or maximum tolerated dose), an ACEI (or ARB) and an MRA. 180 The European Medicines Agency (EMA) approved ivabradine for use in Europe in patients with HFrEF with LVEF ≤35% and in sinus rhythm with a resting heart rate ≥75 bpm, because in this group ivabradine conferred a survival benefit 193 based on a retrospective subgroup analysis requested by the EMA. Practical guidance on how to use ivabradine is given in Web Table 7 .8.
Angiotensin II type I receptor blockers
ARBs are recommended only as an alternative in patients intolerant of an ACEI.
182 Candesartan has been shown to reduce cardiovascular mortality. 182 Valsartan showed an effect on hospitalization for HF (but not on all-cause hospitalizations) in patients with HFrEF receiving background ACEIs.
194
The combination of ACEI/ARB for HFrEF was reviewed by the EMA, which suggested that benefits are thought to outweigh risks only in a select group of patients with HFrEF in whom other treatments are unsuitable. Therefore, ARBs are indicated for the treatment of HFrEF only in patients who cannot tolerate an ACEI because of serious side effects. The combination of ACEI/ARB should be restricted to symptomatic HFrEF patients receiving a beta-blocker who are unable to tolerate an MRA, and must be used under strict supervision.
Combination of hydralazine and isosorbide dinitrate
There is no clear evidence to suggest the use of this fixed-dose combination therapy in all patients with HFrEF. Evidence on the clinical utility of this combination is scanty and comes from one relatively small RCT conducted exclusively in men and before ACEIs or beta-blockers were used to treat HF.
184 A subsequent RCT conducted in self-identified black patients (defined as being of African descent) showed that addition of the combination of hydralazine and isosorbide dinitrate to conventional therapy (ACEI, beta-blocker and MRA) reduced mortality and HF hospitalizations in patients with HFrEF and NYHA Classes III -IV. 183 The results of this study are difficult to translate to patients of other racial or ethnic origins. Additionally, a combination of hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither ACEI nor ARB (or they are contraindicated) to reduce mortality. However, this recommendation is based on the results of the Veterans Administration Cooperative Study, which recruited symptomatic HFrEF patients who received only digoxin and diuretics. 7.4 Other treatments with less certain benefits in symptomatic patients with heart failure with reduced ejection fraction This section describes treatments that have shown benefits in terms of symptomatic improvement, reduction in HF hospitalizations or both, and are useful additional treatments in patients with HFrEF.
Digoxin and other digitalis glycosides
Digoxin may be considered in patients in sinus rhythm with symptomatic HFrEF to reduce the risk of hospitalization (both all-cause and HF hospitalizations), 185 although its effect on top of betablockers has never been tested. The effects of digoxin in patients with HFrEF and AF have not been studied in RCTs, and recent studies have suggested potentially higher risk of events (mortality and HF hospitalization) in patients with AF receiving digoxin. 195, 196 However, this remains controversial, as another recent meta-analysis concluded on the basis of non-RCTs that digoxin has no deleterious effect on mortality in patients with AF and concomitant HF, most of whom had HFrEF.
197
In patients with symptomatic HF and AF, digoxin may be useful to slow a rapid ventricular rate, but it is only recommended for the treatment of patients with HFrEF and AF with rapid ventricular rate when other therapeutic options cannot be pursued. 196,198 -201 Of note, the optimal ventricular rate for patients with HF and AF has not been well established, but the prevailing evidence suggests that strict rate control might be deleterious. A resting ventricular rate in the range of 70 -90 bpm is recommended based on current opinion, although one trial suggested that a resting ventricular rate of up to 110 bpm might still be acceptable. 202 This should be tested and refined by further research. Digitalis should always be prescribed under specialist supervision. Given its distribution and clearance, caution should be exerted in females, in the elderly and in patients with reduced renal function. In the latter patients, digitoxin should be preferred.
7.4.2 n-3 polyunsaturated fatty acids n-3 polyunsaturated fatty acids (n-3 PUFAs) have shown a small treatment effect in a large RCT.
186 n-3 PUFA preparations differ in composition and dose. Only preparations with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethyl esters of at least 85% (850 mg/g) have shown an effect on the cumulative endpoint of cardiovascular death and hospitalization. No effect of n-3 PUFA preparations containing ,850 mg/g has been shown in either HFrEF or post-myocardial infarction. 203 n-3 PUFA preparations containing 850 -882 mg of EPA and DHA as ethyl esters in the average ratio of 1 : 1.2 may be considered as an adjunctive therapy in patients with symptomatic HFrEF who are already receiving optimized recommended therapy with an ACEI (or ARB), a beta-blocker and an MRA.
7.5 Treatments not recommended (unproven benefit) in symptomatic patients with heart failure with reduced ejection fraction 7.5.1 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ('statins') Although statins reduce mortality and morbidity in patients with atherosclerotic disease, statins are not effective in improving the prognosis in patients with HFrEF. Most statin trials excluded patients with HF (because it was uncertain that they would benefit). 204 The two major trials that studied the effect of statin treatment in patients with chronic HF did not demonstrate any evidence of benefit. 205 Therefore, evidence does not support the initiation of statins in most patients with chronic HF.
However, in patients who already receive a statin because of underlying CAD or/and hyperlipidaemia, a continuation of this therapy should be considered.
Oral anticoagulants and antiplatelet therapy
Other than in patients with AF (both HFrEF and HFpEF), there is no evidence that an oral anticoagulant reduces mortality/morbidity compared with placebo or aspirin. 206, 207 Studies testing the nonvitamin K antagonist oral anticoagulants (NOACs) in patients with HFrEF are currently ongoing. Patients with HFrEF receiving oral anticoagulation because of concurrent AF or risk of venous thromboembolism should continue anticoagulation. Detailed information is provided in Section 10.1. Similarly, there is no evidence on the benefits of antiplatelet drugs (including acetylsalicylic acid) in patients with HF without accompanying CAD, whereas there is a substantial risk of gastrointestinal bleeding, particularly in elderly subjects, related with this treatment.
Renin inhibitors
Aliskiren (direct renin inhibitor) failed to improve outcomes for patients hospitalized for HF at 6 months or 12 months in one study 208 and is not presently recommended as an alternative to an ACEI or ARB.
Treatments (or combinations of treatments) that may cause harm in patients with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.
III B
211-213
Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization.
III C 214
The addition of an ARB (or renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with HF, because of the increased risk of renal dysfunction and hyperkalaemia.
III C
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; COX-2 inhibitor ¼ cyclooxygenase-2 inhibitor; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; NSAIDs ¼ non-steroidal anti-inflammatory drugs. a Class of recommendation. There is a variety of dihydropyridine CCBs; some are known to increase sympathetic tone and they may have a negative safety profile in HFrEF. There is only evidence on safety for amlodipine 215 
Implantable cardioverter-defibrillator
A high proportion of deaths among patients with HF, especially those with milder symptoms, occur suddenly and unexpectedly. Many of these are due to electrical disturbances, including ventricular arrhythmias, bradycardia and asystole, although some are due to coronary, cerebral or aortic vascular events. Treatments that improve or delay the progression of cardiovascular disease will reduce the annual rate of sudden death, but they may have little effect on lifetime risk and will not treat arrhythmic events when they occur. ICDs are effective in preventing bradycardia and correcting potentially lethal ventricular arrhythmias. Some antiarrhythmic drugs might reduce the rate of tachyarrhythmias and sudden death, but they do not reduce overall mortality and may increase it.
Secondary prevention of sudden cardiac death
Compared with amiodarone treatment, ICDs reduce mortality in survivors of cardiac arrest and in patients who have experienced sustained symptomatic ventricular arrhythmias. An ICD is recommended in such patients when the intent is to increase survival; the decision to implant should take into account the patient's view and their quality of life, the LVEF (survival benefit is uncertain when the LVEF is .35%) and the absence of other diseases likely to cause death within the following year.
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Recommendations for implantable cardioverter-defibrillator in patients with heart failure 
Secondary prevention
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status.
I A 223-226
Primary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II-III), and an LVEF ≤35% despite ≥3 months of OMT, provided they are expected to survive substantially longer than one year with good functional status, and they have:
• IHD (unless they have had an MI in the prior 40 days -see below 246, 248 should not be used for prevention of arrhythmias in this population. Some guideline-recommended therapies, including betablockers, MRAs, sacubitril/valsartan and pacemakers with CRT (CRT-Ps), reduce the risk of sudden death (see Section 7).
An ICD reduces the rate of sudden arrhythmic death in patients with HFrEF. 249, 250 In patients with moderate or severe HF, a reduction in sudden death may be partially or wholly offset by an increase in death due to worsening HF. 227 In patients with mild HF (NYHA II), an ICD will prevent about two deaths per year for every 100 devices implanted. 227 On average, patients with IHD are at greater risk of sudden death than patients with DCM and therefore, although the relative benefits are similar, the absolute benefit is greater in patients with IHD. 249 Patients with longer QRS durations may also receive greater benefit from an ICD, but these patients should often receive a CRT device.
227,251
Two RCTs showed no benefit in patients who had an ICD implanted within 40 days after a myocardial infarction.
158,228 Although sudden arrhythmic deaths were reduced, this was balanced by an increase in non-arrhythmic deaths. Accordingly, an ICD is contraindicated in this time period. A wearable defibrillator may be considered if the patient is deemed to be at high risk of ventricular fibrillation, although evidence from randomized trials is lacking.
-241
ICD implantation is recommended only after a sufficient trial (minimum 3 months) of optimal medical therapy (OMT) has failed to increase the LVEF to .35%. However, one of the two landmark papers on which these recommendations are based included patients with an LVEF .30%. Fewer than 400 patients with an LVEF of 30 -35% were included in the landmark studies, and although there was no statistical interaction between treatment effect and LVEF, the evidence of benefit is less robust in this group of patients.
Conservative programming with long delays 252 between detection and the ICD delivering therapy dramatically reduces the risk of both inappropriate (due to artefacts or AF) and appropriate but unnecessary [due to self-terminating ventricular tachycardia (VT)] shocks.
-254
Patients with a QRS duration ≥130 ms should be considered for a defibrillator with CRT (CRT-D) rather than ICD. See the guideline on CRT for further details (Section 8.2).
ICD therapy is not recommended in patients in NYHA Class IV with severe symptoms refractory to pharmacological therapy who are not candidates for CRT, a ventricular assist device or cardiac transplantation, because such patients have a very limited life expectancy and are likely to die from pump failure.
Patients with serious co-morbidities who are unlikely to survive substantially more than 1 year are unlikely to obtain substantial benefit from an ICD. 229 -233 Patients should be counselled as to the purpose of an ICD, complications related to implantation and device activation (predominantly inappropriate shocks) and under what circumstances it might be deactivated (terminal disease) or explanted (infection, recovery of LV function).
255
If HF deteriorates, deactivation of a patient's ICD may be considered after appropriate discussion with the patient and caregiver(s).
If the ICD generator reaches its end of life or requires explantation, it should not automatically be replaced. 234 -238 Patients should be carefully evaluated by an experienced cardiologist before generator replacement. Treatment goals may have changed and the risk of fatal arrhythmia may be lower or the risk of non-arrhythmic death higher. It is a matter of some controversy whether patients whose LVEF has greatly improved and who have not required device therapy during the lifetime of the ICD should have another device implanted.
-238
Subcutaneous defibrillators may be as effective as conventional ICDs with a lower risk from the implantation procedure. 256, 257 They may be the preferred option for patients with difficult access or who require ICD explantation due to infection. Patients must be carefully selected, as they have limited capacity to treat serious bradyarrhythmia and can deliver neither antitachycardia pacing nor CRT. Substantial RCTs with these devices and more data on safety and efficacy are awaited. 258, 259 A wearable ICD (an external defibrillator with leads and electrode pads attached to a wearable vest) that is able to recognize and interrupt VT/ventricular fibrillation may be considered for a limited period of time in selected patients with HF who are at high risk for sudden death but otherwise are not suitable for ICD implantation (e.g. those with poor LVEF after acute myocardial damage until LV function recovers, patients scheduled for heart transplantation). 239 -241,260 Use judgement for patients with end-stage HF who might be managed conservatively rather than with treatments to improve symptoms or prognosis.
then the majority of evidence lies with CRT-D for patients in NYHA Class II and with CRT-P for patients in NYHA Classes III -IV. It is unclear whether CRT reduces the need for an ICD (by reducing the arrhythmia burden) or increases the benefit from an ICD (by reducing mortality rates from worsening HF, leading to longer exposure to the risk of arrhythmia).
When LVEF is reduced, RV pacing may exacerbate cardiac dyssynchrony. This can be prevented by CRT, which might improve patient outcomes. 274, 275, 277, 290 The reader is directed to guidelines on pacing and CRT for recommendations on device implantation procedures. The value of trying to optimize AV or VV intervals after implantation using echo-or electrocardiographic criteria or blood pressure response is uncertain, but may be considered for patients who have had a disappointing response to CRT. Cardiac contractility modulation (CCM) is similar in its mode of insertion to CRT, but it involves non-excitatory electrical stimulation of the ventricle during the absolute refractory period to enhance contractile performance without activating extra systolic contractions. CCM has been evaluated in patients with HFrEF in NYHA Classes II -III with normal QRS duration (,120 ms). 221, 222 An individual patient data meta-analysis demonstrated an improvement in exercise tolerance (peak VO 2 ) and quality of life (Minnesota Living with Heart Failure questionnaire). Thus CCM may be considered in selected patients with HF. The effect of CCM on HF morbidity and mortality remains to be established.
Most other devices under evaluation involve some modification of the activity of the autonomic nervous system (ANS) by targeted electrical stimulation.
298,299 These include vagal nerve stimulation, spinal cord stimulation, carotid body ablation and renal denervation, but so far none of the devices has improved symptoms or outcomes in RCTs. Devices for remote monitoring are discussed in Section 14.
9. Treatment of heart failure with preserved ejection fraction The optimal ventricular rate in patients with HFmrEF/HFpEF and AF is uncertain, and aggressive rate control might be deleterious. Whether digoxin, beta-blockers or rate-limiting CCBs, or a combination of these, should be preferred is unknown. Verapamil or diltiazem should not be combined with a beta-blocker. There are insufficient data to recommend ablation strategies (either pulmonary venous or AV node) for HFpEF and HFmrEF.
Circumstantial evidence suggests that treating hypertension, often predominantly systolic, is important in HFmrEF/HFpEF. 127, 317 Diuretics, ACEIs, ARBs and MRAs all appear appropriate agents, but beta-blockers may be less effective in reducing SBP. A recent study suggests that patients with hypertension and HFpEF or HFmrEF should not receive an ARB (olmesartan) if they are receiving ACEIs and beta-blockers.
318
The first-line oral hypoglycaemic drug for patients with HFpEF and HFmrEF should be metformin 319 (see also Section 11.6). Recently, a trial of empagliflozin showed a reduction in blood pressure and body weight, probably by inducing glycosuria and osmotic diuresis. Its use was associated with a reduction in hospitalization for HF and in cardiovascular mortality. 130 However, aggressive management of dysglycaemia may be harmful.
153,320
Myocardial ischaemia may contribute to symptoms, morbidity and mortality and should be considered when assessing patients. However, there is only anecdotal evidence that revascularization improves symptoms or outcome. Patients with angina should follow the same management route as patients with HFrEF.
112
Patients with HFpEF and HFmrEF have impaired exercise tolerance, commonly accompanied by an augmented blood pressure response to exercise and chronotropic incompetence. Combined endurance/resistance training appears safe for patients with HFpEF and HFmrEF and improves exercise capacity (as reflected by an increase in peak oxygen consumption), physical functioning score and diastolic function.
307,321
Recommendations for treatment of patients with heart failure with preserved ejection fraction and heart failure with mid-range ejection fraction 
Arrhythmias and conductance disturbances
Ambulatory electrocardiographic monitoring can be used to investigate symptoms that may be due to arrhythmias, 322 -324 but evidence is lacking to support routine, systematic monitoring for all patients with HF to identify tachy-and bradyarrhythmias. There is no evidence that clinical decisions based on routine ambulatory electrocardiographic monitoring improve outcomes for patients with HF. Ambulatory electrocardiographic recording detects premature ventricular complexes in virtually all patients with HF. Episodes of asymptomatic, non-sustained VT are common, increasing in frequency with the severity of HF and ventricular dysfunction and indicating a poor prognosis in patients with HF, but provide little discrimination between sudden death or death due to progressive HF. 316, 325 Bradycardia and pauses are also commonly observed, especially at night when sympathetic activity is often lower and parasympathetic activity higher; sleep apnoea may be a trigger. 326 -328 Pauses are associated with a poor prognosis in patients with CAD and left ventricular dysfunction. 329 Bradyarrhythmias may make an important contribution to sudden death in HF. The following issues need to be considered in patients with HF presenting with AF, irrespective of LVEF, especially with a first diagnosed episode of AF or paroxysmal AF:
316 † identification of potentially correctable causes (e.g. hypothyroidism or hyperthyroidism, electrolyte disorders, uncontrolled hypertension, mitral valve disease) and precipitating factors (e.g. recent surgery, chest infection or exacerbation of COPD/ asthma, acute myocardial ischaemia, alcohol binge), as this may determine management strategy; † assessment of stroke risk and need for anticoagulation; † assessment of ventricular rate and need for rate control; † evaluation of symptoms of HF and AF.
For details, the reader should refer to the 2016 ESC guidelines on AF. 
I C
For patients in NYHA Class IV, in addition to treatment for AHF, an intravenous bolus of amiodarone or, in digoxin-naïve patients, an intravenous bolus of digoxin should be considered to reduce the ventricular rate.
IIa B 348, 349
For patients in NYHA Class I-III, a beta-blocker, usually given orally, is safe and therefore is recommended ventricular rate, provided the patient is euvolaemic.
I A 177
For patients in NYHA Class I-III, digoxin, should be considered when ventricular rate remains high d despite beta-blockers or when beta-blockers are not tolerated or contra-indicated.
IIa B 197
AV node catheter ablation may be considered to control heart rate and relieve symptoms in patients unresponsive or intolerant to intensive pharmacological rate and rhythm control therapy, accepting that these patients will become pacemaker dependent.
IIb B 290
Treatment with dronedarone to improve ventricular rate control is not recommended due to safety concerns.
III A 347
AF ¼ atrial fibrillation; AHF ¼ acute heart failure; AV ¼ atrio-ventricular; bpm ¼ beats per minute; HF ¼ heart failure; NYHA ¼ New York Heart Association. a Class of recommendation. tain which approach is optimal, but beta-blockers appear safe as the first-line agent even if it is not clear that they reduce morbidity and mortality in patients with AF. Beta-blockers reduce ventricular rate during periods of activity, while digoxin exerts a greater effect at night. 358 Persistently high ventricular rates may indicate thyrotoxicosis or excessive sympathetic activity due to congestion, which might respond to diuresis. Although amiodarone and nondihydropyridine CCBs can reduce ventricular rate, they have more adverse effects and should generally be avoided in patients with HFrEF and, with less certainty, in patients with HFpEF and HFmrEF. Rarely, ventricular rate cannot be reduced below 100 -110 bpm by pharmacological means alone and AV node ablation with ventricular pacing may be considered; in this situation, for patients with HFrEF, CRT should be considered instead of conventional RV pacing. There is little evidence, other than from registries, to support a strategy of AV node ablation and CRT compared with pharmacological therapy alone in patients with AF and a resting ventricular rate ,100 -110 bpm (see Section 8.2). 281 However, in patients with a fast ventricular rate and intractable symptoms, AV node ablation may be considered. Also, if the patient is indicated for an ICD, AV node ablation with implantation of CRT-D may be a preferred option, especially if the patient has moderate to severe symptoms.
Rhythm control
In patients with chronic HF, a rhythm control strategy (including pharmacological or electrical cardioversion) has not been shown to be superior to a rate control strategy in reducing mortality or morbidity. 359 Urgent cardioversion is indicated only if the AF is life threatening, otherwise both HF and ventricular rate should be controlled prior to cardioversion. A rhythm control strategy is probably best reserved for patients with a reversible secondary cause of AF (e.g. hyperthyroidism) or an obvious precipitant (e.g. recent pneumonia) and in patients with troublesome symptoms due to AF after optimization of rate control and HF therapy. The use of class I antiarrhythmic agents and dronedarone increases morbidity and mortality in patients with HF and AF and should be avoided. 246, 247, 347 Amiodarone will cause some patients with chronic AF to revert to sinus rhythm, may reduce symptomatic paroxysms of AF and will help maintain patients in sinus rhythm after spontaneous or electrical cardioversion. 343 -346 When used, the need for continued administration of amiodarone should be regularly reviewed and justified. The safety and efficacy of catheter ablation in the atria and pulmonary veins (PV) as a rhythm control strategy in HF is at present uncertain except for tachycardia induced cardiomyopathy. 316 One small study suggested that AF ablation was superior to AV node ablation and CRT. 360 Another study, including 203 patients with persistent AF, HF and an ICD or CRT device, showed that AF ablation was superior to amiodarone in correcting AF, and this was associated with fewer hospitalizations for HF and lower mortality. Two small studies of AF ablation compared with rate control met with mixed success in terms of procedural complications and success in improving symptoms. ]. In patients with HF and AF who have mechanical heart valves or at least moderate mitral stenosis, only oral vitamin K antagonists should be used for prevention of thromboembolic stroke.
370
The dabigatran dose should be reduced to 110 mg b.i.d. when creatinine clearance is 30 -49 mL/min, rivaroxaban to 15 mg daily and edoxaban to 30 mg daily when creatinine clearance is 30 -50 mL/ min and apixaban to 2.5 mg twice daily if a patient has two or more of the following: age ≥80 years, serum creatinine ≥1.5 mg/ dL or body weight ≤60 kg. 370 -375 The summary of the recommendations for the prevention of thromboembolism in patients with symptomatic HF and paroxysmal or persistent/permanent AF is presented in the recommendations table. For further details, please refer to the recent ESC guidelines on AF.
316
A left atrial occlusion device could be considered in a patient with AF as an alternative to an oral anticoagulant who is at high-risk both of thromboembolism and of bleeding in order to avoid the risk of haemorrhage due to anticoagulation risk.
381,382
Ventricular arrhythmias
The initial management of asymptomatic ventricular arrhythmias is correction of electrolyte abnormalities, particularly low serum potassium and magnesium, withdrawal of agents that might provoke arrhythmias and, in patients with HFrEF, optimization of pharmacological therapy with ACEIs, beta-blockers and MRAs and sacubitril/valsartan, which all reduce the risk of sudden death. 174, 177, 383, 384 The clinical relevance of myocardial ischaemia for the provocation of ventricular arrhythmias is uncertain, although anecdotal cases of ischaemia-induced arrhythmias exist. Amiodarone (often in combination with a beta-blocker) may be used to suppress symptomatic ventricular arrhythmias, but it may adversely affect prognosis, especially in patients with more severe HF. 227, 244 Other antiarrhythmic drugs should be avoided. 247 Transcatheter radiofrequency modification of the arrhythmogenic substrate may reduce the number of appropriate ICD discharges and may be used to terminate arrhythmic storm in patients with
Recommendations for the prevention of thrombo-embolism in patients with symptomatic heart failure (NYHA Class II -IV) and paroxysmal or persistent/permanent atrial fibrillation An oral anticoagulant is recommended to prevent thrombo-embolism for all patients with paroxysmal or persistent/permanent AF and a CHA2DS2-VASc score ≥2, without contra-indications, and irrespective of whether a rate or rhythm management strategy is used (including after successful cardioversion).
NOAC treatment is contra-indicated in patients with mechanical valves or at least moderate mitral stenosis.
III B 380
In patients with AF of ≥48 h duration, or when the duration of AF is unknown, an oral anticoagulant is recommended at a therapeutic dose for ≥3 weeks prior to electrical or pharmacological cardioversion.
I B
Intravenous heparin or LMWH and TOE quided strategy is recommended for patients who have not been treated with an anticoagulant dose for ≥3 weeks and require urgent electrical or pharmacological cardioversion for a life threatening arrhythmia.
I C
Combination of an oral anticoagulant and an antiplatelet agent is not recommended in patients with chronic (>12 months after an acute event) coronary or other arterial disease, because of a high-risk of serious bleeding. Single therapy with an oral anticoagulant is preferred after 12 months.
III C
For patients with HF and non-valvular AF eligible for anticoagulation based on a CHA2DS2-VASc score, NOACs rather than warfarin should be considered for anticoagulation as NOACs are associated with a lower risk of stroke, intracranial haemorrhage and mortality, which outweigh the increased risk of gastrointestinal haemorrhage. 
IIa
Symptomatic bradycardia, pauses and atrio-ventricular block
The ESC Guidelines on Pacing and CRT recommended intervention when pauses exceed 6 s, even when this is not associated with symptoms. 389 However, these recommendations were generated mainly for patients without obvious myocardial dysfunction, and shorter pauses might require intervention in patients with HFrEF. When pauses >3 seconds are bradycardia is symptomatic and the resting ventricular rate is <50 bpm in sinus rhythm or <60 bpm in AF, it should be considered whether there is need for any rate limiting medications prescribed; for patients in sinus rhythm beta-blockers should be reduced in dose or withdrawn only as a last resort.
IIa C
For patients with symptomatic, prolonged or frequent pauses despite adjustment of rate limiting medication, either beta-blocker withdrawal or pacing may be considered as the next step.
IIb C
Pacing solely to permit initiation or titration of beta-blocker therapy in the absence of a conventional pacing indication is not recommended.
III C
In patients with HFrEF who require pacing and who have high degree AV block, CRT rather than RV pacing is recommended.
I A 274, 275, 290
In patients with HFrEF who require pacing who do not have high degree AV block, pacing modes that avoid inducing or exacerbating ventricular dyssynchrony should be considered. 11. Co-morbidities 11.1. Heart failure and co-morbidities
Co-morbidities are of great importance in HF (Table 11 .1) and may affect the use of treatments for HF (e.g. it may not be possible to use renin -angiotensin system inhibitors is some patients with severe renal dysfunction) (see Section 7). The drugs used to treat comorbidities may cause worsening of HF (e.g. NSAIDs given for arthritis, some anti-cancer drugs) (see Section 7). Management of comorbidities is a key component of the holistic care of patients with HF (see Section 14). Many co-morbidities are actively managed by specialists in the field of the co-morbidity, and these physicians will follow their own specialist guidelines. The current guidelines will identify where the presence of HF should change the way a comorbidity would normally be treated. This may be because either safety or efficacy may be different in the presence of HF (or may simply be unknown) or because of evidence of particular effects in an HF population, either beneficial or detrimental. HFpEF has an even higher prevalence of co-morbidities compared with HFrEF, and many of these may be instrumental in the progression of this syndrome.
398
11.2 Angina and coronary artery disease 11.2.1 Pharmacological management Beta-blockers, and in selected patients ivabradine, 180 are effective agents for angina control, as well as an essential component of HFrEF therapy. In HFpEF patients, they may also be used for angina relief, although this has never been formally tested. In the SIGNIFY trial in patients with activity-limiting angina without HF, ivabradine increased the risk of death from cardiovascular causes or non-fatal myocardial infarction and therefore is not recommended in this setting.
399
Trimetazidine has been shown to exert some beneficial effect as an add-on to beta-blockers in patients with HF and angina. 400 -406 There are data suggesting that it may improve NYHA functional capacity, exercise duration and LV function in patients with HFrEF. 402 -406 
Myocardial revascularization
For indications for invasive coronary angiography in patients with HF, please refer to Section 5.8. Percutaneous and surgical revascularization are complementary approaches for symptomatic relief of angina in HFpEF, but whether these interventions improve outcomes is not entirely clear. Recent ESC guidelines on myocardial revascularization recommended coronary artery bypass grafting (CABG) for patients with significant left main stenosis and left main equivalent (proximal stenosis of both the left anterior descending and left circumflex arteries) to improve prognosis. 112, 113 However, one needs to be aware of a lack of studies including patients who have well-defined HF, therefore this recommendation is solely based on expert opinion. On the basis of the results of the STICH trial [which excluded patients with left main disease and Canadian Cardiovascular Society (CCS) angina classes III -IV], CABG is also recommended in patients with HFrEF, significant CAD (left anterior descending artery or multivessel disease) and LVEF ≤35% to reduce death and hospitalization for cardiovascular causes. 385 Patients with .10% dysfunctional but viable LV myocardium may be more likely to benefit from myocardial revascularization (and those with ≤10% are less likely to benefit), although this approach to patient selection for revascularization is unproven. In the STICH trial, neither the presence of viability nor the severity of LV remodelling identified those who benefited from CABG in terms of a reduction in mortality.
118
For the assessment of techniques to assess myocardial viability, please refer to Section 5. Post hoc analyses from the STICH trial revealed that the presence of inducible myocardial ischaemia (either on radionuclide stress test or dobutamine stress echocardiogram) or angina does not identify those with worse prognosis and greater benefit from CABG over OMT. 115, 386 However, CABG does improve angina to a greater extent than medical therapy alone.
The choice between CABG and PCI should be made by the Heart Team after careful evaluation of the patient's clinical status and coronary anatomy, expected completeness of revascularization, coexisting valvular disease and co-morbidities. Table 11 .1 Importance of co-morbidities in patients with heart failure 1. interfere with the diagnostic process of HF (e.g. COPD as a potentially confounding cause of dyspnoea). 390, 391 2. aggravate HF symptoms and further impair quality of life. 391, 392 3. contribute to the burden of hospitalizations and mortality, 393 as the main cause of readmissions at 1 and 3 months. 4. may affect the use of treatments for HF (e.g. renin-angiotensin system inhibitors contra-indicated in some patients with severe renal dysfunction or beta-blockers relatively contra-indicated in asthma). 395, 396 5. evidence base for HF treatment is more limited as co-morbidities were is therefore often lacking in the presence of co-morbidities.
6. drugs used to treat co-morbidities may cause worsening HF (e.g. NSAIDs given for arthritis, some anti-cancer drugs). 397 7. interaction between drugs used to treat HF and those used to treat occurrence of side effects (e.g. beta-blockers for HFrEF and betaagonists for COPD and asthma). 391, 395, 396 HF ¼ heart failure; COPD ¼ chronic obstructive pulmonary disease; HFrEF ¼ heart failure with reduced ejection fraction; NSAIDs ¼ non-steroidal anti-inflammatory drugs.
Cachexia and sarcopenia (for frailty, please refer to Section 14)
Cachexia is a generalized wasting process affecting all body compartments [i.e. lean tissue (skeletal muscle), fat tissue (energy reserves) and bone tissue (osteoporosis)]. It may occur in 5-15% of patients with HF, especially those with HFrEF, and more advanced disease status. 414 -416 This serious complication is associated with more severe symptoms and reduced functional capacity, more frequent hospitalization and decreased survival. Cachexia in HF can be diagnosed and defined as involuntary non-oedematous weight loss ≥6% of total body weight within the previous 6-12 months.
-417
The causes are multifactorial, and in individual patients they are difficult to determine. These may include pro-inflammatory immune activation, neurohormonal derangements, poor nutrition and malabsorption, impaired calorie and protein balance, anabolic hormone resistance, reduced anabolic drive, prolonged immobilization and physical deconditioning, together characterized by catabolic/anabolic imbalance. 418 Skeletal muscle wasting, when associated with impaired mobility and symptoms (termed sarcopenia or myopenia), occurs in 30 -50% of patients with HFrEF. 419 In its most severe form it is associated with frailty and poor morbidity and mortality.
420
Potential treatments may include appetite stimulants, exercise training 120 and anabolic agents, including testosterone, in combination with the application of nutritional supplements and anti-catabolic interventions, although none is of proven benefit and their safety is unknown. Step 1
Step 2: on top of beta-blocker or if a beta-blocker is not tolerated Ivabradine should be considered as an anti-anginal drug in suitable HFrEF patients (sinus rhythm and HR ≥70 bpm) as per recommended HFrEF management. IIa B 180, 410, 411
Step 3: For additional angina symptom relief -except from any combination not recommended A short-acting oral or transcutaneous nitrate should be considered (effective anti-anginal treatment, safe in HF). IIa A 183, 184, 409
A long acting oral or transcutaneous nitrate should be considered (effective anti-anginal treatment, not extensively studied in HF). IIa B 183, 184
Trimetazidine may be considered when angina persists despite treatment with a beta-blocker (or alternative) to relieve angina (effective anti-anginal treatment, safe in HF). IIb A 400-403
Amlodipine may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, safe in HF).
IIb B 215, 407
Nicorandil may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, but safety in HF uncertain).
IIb C
Ranolazine may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, but safety in HF uncertain).
IIb C Step 4: Myocardial revascularization
Myocardial revascularization is recommended when angina persists despite treatment with anti-angina drugs. I A 385, 412, 413
Alternatives to myocardial revascularization: combination of ≥3 antianginal drugs (from those listed above) may be considered when angina persists despite treatment with beta-blocker, ivabradine and an extra anti-angina drug (excluding the combinations not recommended below).
IIb C
The following are NOT recommended:
(1) Combination of any of ivabradine, ranolazine, and nicorandil because of unknown safety.
III C
(2) Combination of nicorandil and a nitrate (because of lack of III C Diltiazem and verapamil are not recommended because of their negative inotropic action and risk of worsening HF.
III C 214
bpm ¼ beats per minute; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; NYHA ¼ New York Heart Association. a Class of recommendation. 11.5 Central nervous system (including depression, stroke and autonomic dysfunction)
Stroke and HF commonly coexist because of an overlap of shared risk factors. Both contribute to a worse prognosis. Stroke may make self-care more difficult for the HF patient. Management of high-risk stroke patients may require balancing the risk of anticoagulant and antiplatelet therapies. Autonomic dysfunction is common in HFrEF, especially when severe. 427 Combined with low blood pressure, it can make fainting and injuries more likely and can interfere with optimal dosing of betablockers, ACEIs, ARBs and MRAs. Diuretic dosage may be reduced to reduce the severity of postural hypotension. Depression is common and is associated with worse clinical status and a poor prognosis in HF. 428 -430 It may also contribute to poor adherence and social isolation. A high index of suspicion is needed to make the diagnosis, especially in the elderly. Routine screening using a validated questionnaire is good practice. Until now, the Beck Depression Inventory (BDI) and Cardiac Depression Scale have been formally validated as reliable tools for the assessment of depressive mood in patients with HF, 431,432 but other questionnaires have been broadly used in this group of patients (e.g. Geriatric Depression Scale, Hamilton Depression Scale, Hospital Anxiety and Depression Scale). Psychosocial intervention and pharmacological treatment are helpful, as well as exercise training, in patients with HFrEF and depression. 433 Cognitive behavioural therapy delivered in patients with HF and major depression beyond standard care and a structured education programme were able to reduce depression severity, anxiety and fatigue symptoms, as well as improve social functioning and mental and HF-related quality of life.
434
Selective serotonin reuptake inhibitors are thought to be safe, although the Sertraline Antidepressant Heart Attack Randomized Trial did not confirm that sertraline provides a greater reduction in depressive symptoms or improvement in cardiovascular status compared with placebo in HFrEF patients, but this trial was not powered enough to prove the latter. 435 Similarly, escitalopram had no effect on either depression or clinical outcomes during the 24-month follow-up as compared with placebo in patients with HFrEF and depression. Importantly, tricyclic antidepressants should be avoided, because they may cause hypotension, worsening HF and arrhythmias. In patients with diabetes and HF, glycaemic control should be implemented gradually and moderately, giving preference to those drugs, such as metformin, that have been shown to be safe and effective. In contrast to what was previously believed, metformin is safe to use in patients with HFrEF, and it should be the treatment of choice in patients with HF 440,441 but is contraindicated in patients with severe renal or hepatic impairment, because of the risk of lactic acidosis.
Insulin is required for patients with type 1 diabetes and to treat symptomatic hyperglycaemia in patients with type 2 diabetes and pancreatic islet b cell exhaustion. However, insulin is a powerful sodium-retaining hormone, and when combined with a reduction in glycosuria, may exacerbate fluid retention, leading to HF worsening. Sulphonylurea derivatives have also been associated with an increased risk of worsening HF and should be used with caution.
Thiazolidinediones (glitazones) cause sodium and water retention and increased risk of worsening HF and hospitalization and are not recommended in patients with HF. 209, 210 Dipeptidylpeptidase-4 inhibitors (DPP4is; gliptins), which increase incretin secretion, thereby stimulating insulin release, and longacting glucagon-like peptide 1 (GLP-1) receptor agonists, which act as incretin mimetics, improve glycaemic indices but do not reduce and may increase the risk of cardiovascular events and worsening HF. 320, 442, 443 Importantly, there are no data on the safety of gliptins and GLP-1 analogues in patients with HF. Recently, empagliflozin, an inhibitor of sodium-glucose cotransporter 2, reduced hospitalization for HF and mortality, but not myocardial infarction or stroke, in patients with diabetes at high cardiovascular risk, some of whom had HF. 130 In the absence of other studies with drugs from this group, the results obtained with empaglifozin cannot be considered as a proof of a class effect.
As glycaemic derangement progresses, the judgement on glycaemic control should be made according to cardiac conditions, and if the new anti-diabetic drugs are to be prescribed, they have to be closely monitored by an HF team.
Erectile dysfunction
Erectile dysfunction is a common and important component of quality of life in men with HF.
444 
Gout and arthritis
Hyperuricaemia and gout are common in HF and may be caused or aggravated by diuretic treatment. Hyperuricaemia is associated with a worse prognosis in HFrEF. 448 The current European League Against Rheumatism (EULAR) guideline for the management of gout recommends that urate-lowering therapy (ULT) is indicated in patients with recurrent acute flares, arthropathy, tophi or radiographic changes of gout, aiming to maintain a serum urate level below the saturation point for monosodium urate [,357 mmol/L (,6 mg/dL)].
449
Xanthine oxidase inhibitors (allopurinol, oxypurinol) may be used to prevent gout, although their safety in HFrEF is uncertain. 450 Gout attacks are better treated with colchicine rather than with NSAIDs (although colchicine should not be used in patients with very severe renal dysfunction and may cause diarrhoea). Intra-articular corticosteroids are an alternative for monoarticular gout, but systemic corticosteroids cause sodium and water retention. Arthritis is a common co-morbidity and is a common cause of both self-taken and prescribed drugs that can worsen renal function and HF, especially NSAIDs. Rheumatoid arthritis is associated with an increased risk of HFpEF. The safety of disease-modifying drugs commonly given to patients with rheumatoid arthritis has not been established in HF.
Hypokalaemia and hyperkalaemia
Both hypokalaemia and hyperkalaemia are associated with HF and with many drugs used for HF treatment.
451 Both can aggravate ventricular arrhythmias. Loop and thiazide diuretics reduce serum potassium, while ACEIs, ARBs and MRAs can all increase serum potassium. Amiloride and triamterene are sometimes used as adjunct diuretics in resistant oedema and to assist in preventing hypokalaemia. The treatment of hypokalaemia can involve recommending high potassium foods or prescribing potassium supplements. 
Hypertension
Hypertension is associated with an increased risk of developing HF; antihypertensive therapy markedly reduces the incidence of HF (with an exception of a-adrenoceptor blockers, which are less effective than other antihypertensives in preventing HF). 458 A recent prospective cohort study documented that in a population with incident HF, higher baseline systolic, diastolic and pulse pressure levels were associated with a higher rate of adverse events, which further supports the importance for optimized blood pressure control in this population. 459 Blood pressure control is an element of the holistic management of patients with HF. Negatively inotropic CCBs (i.e. diltiazem and verapamil) should not be used to treat hypertension in patients with HFrEF (but are believed to be safe in HFpEF), and moxonidine should also be avoided in patients with HFrEF, as it increased mortality in patients in one RCT. 460 
Iron deficiency and anaemia
Iron deficiency is common in HF, as it is with other chronic illnesses, and it can lead to anaemia and/or skeletal muscle dysfunction without anaemia. 466 Within an HF population, iron deficiency is associated with a worse prognosis. 467, 468 Intravenous iron has been specifically studied in two RCTs in patients with HF and iron deficiency (serum ferritin ,100 mg/L or ferritin between 100 and 299 mg/L and transferrin saturation ,20%) Step 1
They are also safe in HFpEF. 2, 164, 165, 167, 168, 171-174, 182, 461-463 Step 2 A thiazide diuretic (or if the patient is being treated with a thiazide diuretic, switching to a loop diuretic) is recommended to reduce blood pressure when hypertension persists despite treatment with a combination of an ACE-I (or alternatively ARB but NOT together withan ACE-I), a beta-blocker and an MRA.
I A
I C
Step 3
Amlodipine or hydralazine is recommended to reduce blood pressure when hypertension persists despite treatment with a combination of an ACE-I (or alternatively ARB but NOT together withan ACE-I), a beta-blocker, an MRA and a diuretic. I A 183, 184, 215, 409
Felodipine should be considered to reduce blood pressure when hypertension persists despite treatment with a combination of an ACE-I (or alternatively ARB but NOT together withan ACE-I), a beta-blocker, an MRA and a diuretic.
IIa B 216
Moxonidine is not recommended to reduce blood pressure because of safety concerns in HFrEF patients (increased mortality).
III B 460
Alpha-adrenoceptor antagonists are not recommended to reduce blood pressure because of safety concerns in HFrEF patients III A 458, 464, 465
Diltiazem and verapamil are not recommended to reduce blood pressure in patients with HFrEF because of their negative inotropic action and risk of worsening HF.
III C 214
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; HF ¼ heart failure; HFmrEF ¼ heart failure with mid-range ejection fraction; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; NYHA ¼ New York Heart Association. Anaemia (defined as a haemoglobin concentration ,13.0 g/dL in men and ,12.0 g/dL in women) is common in HF, particularly in hospitalized patients. It is more common in women, the elderly and in patients with renal impairment and is associated with advanced myocardial remodelling, inflammation and volume overload. 474 Anaemia is associated with advanced symptoms, worse A further deterioration in renal function, termed worsening renal function (WRF), is used to indicate an increase in serum creatinine, usually by .26.5 mmol/L (0.3 mg/dL) and/or a 25% increase or a 20% drop in GFR. The importance of these apparently small changes is that they are frequent, they promote the development and progression of CKD 478 and, as a consequence, can worsen the prognosis of HF. Increases in creatinine during an AHF hospitalization are not always clinically relevant, especially when they are accompanied by appropriate decongestion, diuresis and haemoconcentration.
479
Large increases in serum creatinine, termed acute kidney injury (AKI), are relatively rare in HF and are probably associated with the combination of diuretic therapy with other potentially nephrotoxic drugs such as some antibiotics (gentamicin and trimethoprim), contrast media, ACEIs, ARBs, NSAIDs, etc. Of relevance, some of these drugs may accumulate if they are renally excreted. In HF, WRF is relatively common, especially during initiation and uptitration of RAAS inhibitor therapy. Despite the fact that RAAS blockers can frequently cause a decrease in GFR in patients with HF, this reduction is usually small and should not lead to treatment discontinuation unless there is a marked decrease, as the treatment benefit in these patients is probably largely maintained.
480 When large increases in serum creatinine occur, care should be taken to evaluate the patient thoroughly and should include assessment of a possible renal artery stenosis, excessive hyper-or hypovolaemia, concomitant medication and hyperkalaemia, which frequently coincides with WRF. Diuretics, especially thiazides, but also loop diuretics, may be less effective in patients with a very low GFR, and if used, should be dosed appropriately (higher doses to achieve similar effects). Renally excreted drugs (e.g. digoxin, insulin and low molecular weight heparin) may accumulate in patients with renal impairment and may need dose adjustment if renal function deteriorates. Patients with HF and coronary or peripheral vascular disease are at risk of acute renal dysfunction when they undergo contrast media enhanced angiography [contrast-induced acute kidney injury (CI-AKI)]. Renal dysfunction and worsening renal function is further discussed in the section about AHF (see Section 12).
Prostatic obstruction is common in older men and can interfere with renal function; it should therefore be ruled out in men with HF with deteriorating renal function. a-adrenoceptor blockers cause hypotension and sodium and water retention, and may not be safe in HFrEF. 458, 464, 465 For these reasons, 5-a-reductase inhibitors are generally preferred in the medical treatment of prostatic obstruction in patients with HF.
11.14 Lung disease (including asthma and chronic obstructive pulmonary disease)
The diagnosis of COPD and asthma may be difficult in patients with HF, due to overlap in symptoms and signs, but also problems in the interpretation of spirometry, especially in HFpEF. contraindication, but these medications should only be used under close medical supervision by a specialist, with consideration of the risks for and against their use. The long-term safety of cardioactive inhaled pulmonary drugs is uncertain and the need for their use should be reconsidered in patients with HFrEF, especially as their benefit in asthma and COPD may be symptomatic only without a clear effect on mortality. Oral corticosteroids can cause sodium and water retention, potentially leading to worsening of HF, but this is not believed to be a problem with inhaled corticosteroids. Pulmonary hypertension can complicate severe long-standing COPD, which, as a result, makes right-sided HF and congestion more likely. Non-invasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary oedema.
Obesity
Obesity is a risk factor for HF 141 and complicates its diagnosis, because it can cause dyspnoea, exercise intolerance and ankle swelling and may result in poor-quality echocardiographic images. Obese individuals also have reduced NP levels. 62 Obesity is more common in HFpEF than in HFrEF, although it is possible that misdiagnosis may explain at least some of this difference in prevalence. Although obesity is an independent risk factor for developing HF, once HF is diagnosed, it is well established that obesity is associated with lower mortality across a wide range of body mass indexes (BMIs) (see also cachexia in Section 11.3)-the so-called obesity paradox also seen in other chronic illnesses. 414, 416 Obesity should be managed as recommended in the ESC guidelines on cardiovascular disease prevention, 483 if the aim is to prevent future development of HF. However, these guidelines do not refer to the HF patient in whom higher BMI is not adverse, and, although often recommended for symptom benefit and risk factor control, weight loss as an intervention has never been prospectively shown to be either beneficial or safe in HFrEF. When weight loss is occurring in HF, it is associated with high mortality and morbidity, worse symptom status and poor quality of life. In patients with HF with moderate degrees of obesity (BMI ,35 kg/m 2 ), weight loss cannot be recommended. In more advanced obesity (BMI 35-45 kg/m 2 ), weight loss may be considered to manage symptoms and exercise capacity.
Sleep disturbance and sleep-disordered breathing
The safety and efficacy of alternative approaches to treating CSA in HFrEF patients, such as implantable phrenic nerve stimulation, 219, 220, 492 are presently undergoing clinical investigation and may require additional long term study.
Valvular heart disease
Valvular heart disease may cause or aggravate HF. This section briefly addresses problems particularly relevant to HF, and the reader is referred to the recent guidelines on valvular disease for more information. 493, 494 Patients with HF and concomitant valvular heart disease constitute a high-risk population. Thus, the whole process of decision-making through a comprehensive evaluation of the risk-benefit ratio of different treatment strategies should be made by a multidisciplinary 'heart team' with a particular expertise in valvular heart disease, including cardiologists with expertise in HF, cardiac surgeons, a structural valve interventionist if a catheter-based therapy is being considered, imaging specialists, anaesthetists and, if needed, general practitioners, geriatricians, or intensive care specialists. This may be particularly beneficial in patients with HF being considered for surgery, transcatheter aortic valve implantation or transcatheter mitral valve intervention.
All patients should receive OMT. In those with HFrEF pharmacological therapy should be planned according to a previously described algorithm (see Section 7 for details). Care must be taken using vasodilators (ACEI, ARBs, CCBs, hydralazine, and nitrates) in patients with severe aortic stenosis in order not to cause hypotension.
Aortic stenosis
The main concern in patients with severe aortic stenosis and reduced LVEF is the entity of 'low-flow, low-gradient' aortic stenosis (valve area , 1 cm 2 , LVEF , 40%, mean pressure gradient , 40 mmHg). In such individuals, low-dose dobutamine stress echocardiography should be considered to differentiate between patients with moderate aortic stenosis, and those with severe stenosis and low flow across the valve due to low stroke volume, and to evaluate for contractile or flow reserve. If the mean gradient is . 40 mmHg, there is theoretically no lower LVEF limit for aortic valve replacement in symptomatic patients with severe aortic stenosis.
Transaortic valve implantation (TAVI) is recommended in patients with severe aortic stenosis who are not suitable for surgery as assessed by a 'heart team' and have predicted post-TAVI survival . 1 year. TAVI should be also considered in high-risk patients with severe aortic stenosis who may still be suitable for surgery, but in whom TAVI is favoured by a 'heart team' based on the individual risk profile and anatomic suitability. 495, 496 In a recent trial in patients with severe aortic stenosis, TAVI with a self-expanding transcatheter aortic valve bioprosthesis was associated with a significantly higher rate of survival at 1 year which was sustained at 2 years. 497, 498 11.17.2. Aortic regurgitation In patients with severe aortic regurgitation, aortic valve repair or replacement is recommended in all symptomatic patients and in asymptomatic patients with resting LVEF ≤ 50%, who are otherwise fit for surgery.
499,500
Mitral regurgitation
This section refers to chronic settings while acute settings are discussed in Section 12.
Primary (organic) mitral regurgitation Surgery is indicated in symptomatic patients with severe organic mitral regurgitation with no contra-indications to surgery. The decision of whether to replace or repair depends mostly on valve anatomy, surgical expertise available, and the patient's condition. When the LVEF is , 30%, a durable surgical repair may improve symptoms, although its effect on survival is unknown. In this situation, the decision to operate should take account of response to medical therapy, co-morbidities, and the likelihood that the valve can be repaired (rather than replaced).
Secondary mitral regurgitation
This occurs because LV enlargement and remodelling lead to reduced leaflet closing. Effective medical therapy (including CRT in suitable patients) leading to reverse remodelling of the LV may reduce functional mitral regurgitation, and every effort should be made to optimize medical treatment in these patients.
Combined valve and coronary surgery should be considered in symptomatic patients with LV systolic dysfunction (LVEF , 30%), coronary arteries suitable for revascularization, and evidence of viability. Surgery is also recommended in patients with severe mitral regurgitation undergoing CABG with LVEF . 30%.
However, a recent study in patients with moderate, secondary ischaemic mitral regurgitation did not prove that the addition of mitral valve repair to CABG would lead to a higher degree of LV reverse remodelling.
501 Also, there is no evidence favouring mitral valve repair over replacement in the context of better outcomes and magnitude of LV remodelling. 502 In the presence of AF, atrial ablation and LA appendage closure may be considered at the time of mitral valve surgery. The role of isolated mitral valve surgery in patients with severe functional mitral regurgitation and severe LV systolic dysfunction (LVEF , 30%) who cannot be revascularized or have non-ischaemic cardiomyopathy is questionable, and in most patients conventional medical and device therapy are preferred. In selected cases, repair may be considered in order to avoid or postpone transplantation. The decision should be based on comprehensive evaluation (including strain echocardiography or magnetic resonance imaging 499, 503 and discussed within the 'heart team'.
In patients with HF with moderate-severe, secondary mitral regurgitation who are judged inoperable or at high surgical risk, percutaneous mitral valve intervention (percutaneous edge-to-edge repair) may be considered in order to improve symptoms and quality of life, although no RCT evidence of improvement has been published, only registry studies. 504 -506 11.17.4. Tricuspid regurgitation Secondary (functional) tricuspid regurgitation (TR) frequently complicates the natural course of HF, due to annular dilatation and increased tricuspid leaflet tethering in relation to RV pressure and/ or volume overload. Severe TR causes/deteriorates symptoms and signs of right HF, thus diuretics are used to reduce peripheral oedema. As hepatic congestion is often present in these patients (additionally contributing to hyperaldosteronism), an addition of an MRA (in higher natriuretic doses) may improve decongestion. 507 Management of HF which underlies secondary TR should be optimized as TR may diminish, following the treatment of its cause. Indications for surgical correction of secondary TR complicating HF are not clearly established. 12. Acute heart failure 12.1 Definition and classification AHF refers to rapid onset or worsening of symptoms and/or signs of HF. It is a life-threatening medical condition requiring urgent evaluation and treatment, typically leading to urgent hospital admission. AHF may present as a first occurrence (de novo) or, more frequently, as a consequence of acute decompensation of chronic HF, and may be caused by primary cardiac dysfunction or precipitated by extrinsic factors, often in patients with chronic HF. Acute myocardial dysfunction (ischaemic, inflammatory or toxic), acute valve insufficiency or pericardial tamponade are among the most frequent acute primary cardiac causes of AHF. Decompensation of chronic HF can occur without known precipitant factors, but more often with one or more factors, such as infection, uncontrolled hypertension, rhythm disturbances or non-adherence with drugs/diet (Table 12.1).
A large number of overlapping classifications of AHF based on different criteria have been proposed. 510 -513 In practice the most useful classifications are those based on clinical presentation at admission, allowing clinicians to identify patients at high risk of complications and to direct management at specific targets, which creates a pathway for personalized care in the AHF setting. In most cases, patients with AHF present with either preserved (90 -140 mmHg) or elevated (.140 mmHg; hypertensive AHF) systolic blood pressure (SBP). Only 5 -8% of all patients present with low SBP (i.e. ,90 mmHg; hypotensive AHF), which is associated with poor prognosis, particularly when hypoperfusion is also present.
514,515
Another approach is to classify patients according to the presence of the following precipitants/causes leading to decompensation, which need to be treated/corrected urgently (see Section 12.3.1): ACS, hypertensive emergency, rapid arrhythmias or severe , LVEF <40%, mean pressure gradient <40 mmHg), low-dose dobutamine stress echocardiography should be considered to identify those with severe aortic stenosis suitable for valve replacement.
IIa C
TAVI is recommended in patients with severe aortic stenosis who are not suitable for surgery as assessed by a 'heart team' and have predicted post-TAVI survival >1 year. I B 495, 496, 509
TAVI should be considered in high-risk patients with severe aortic stenosis who may still be suitable for surgery, but in whom TAVI is IIa A 497, 498
In patients with severe aortic regurgitation, aortic valve repair or replacement is recommended in all symptomatic patients and in asymptomatic patients with resting LVEF ≤ I C 317
Evidence-based medical therapy in patients with HFrEF is recommended in order to reduce functional mitral regurgitation.
I C
Combined surgery of secondary mitral regurgitation and coronary artery bypass grafting should be considered in symptomatic patients with LV systolic dysfunction (LVEF <30%), requiring coronary revascularization for angina recalcitrant to medical therapy.
IIa C
Isolated surgery of non-ischaemic regurgitant mitral valve in patients with severe functional mitral regurgitation and severe LV systolic dysfunction (LVEF <30%) may be considered in selected patients in order to avoid or postpone transplantation. Excessive rise in blood pressure.
Infection (e.g. pneumonia, infective endocarditis, sepsis).
Bradyarrhythmia.
Toxic substances (alcohol, recreational drugs).
Drugs (e.g. NSAIDs, corticosteroids, negative inotropic substances, cardiotoxic chemotherapeutics).
Exacerbation of chronic obstructive pulmonary disease.
Pulmonary embolism.
Surgery and perioperative complications.
Increased sympathetic drive, stress-related cardiomyopathy.
Metabolic/hormonal derangements (e.g. thyroid dysfunction, diabetic ketosis, adrenal dysfunction, pregnancy and peripartum related abnormalities).
Cerebrovascular insult.
Acute mechanical cause: myocardial rupture complicating ACS (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis.
ACS ¼ acute coronary syndromes; NSAIDs ¼ non-steroidal anti-inflammatory drugs.
